Race Oncology Ltd (RAC) is an Australian pharmaceutical company whose business model is to pursue and bring to market later stage assets, principally in the cancer field. The Company’s first important asset is a chemotherapy drug, called Bisantrene, which was the subject of more than 40 phase II clinical studies. On 13 August 2019, the Company announced it had secured a new patent on its cancer drug, Bisantrene, from the United States Patent and Trademarks Office.
Race Oncology Ltd operators in Health Care sector and under industry of Biotechnology. The company website is: http://www.raceoncology.com.
You can also check out dividend history for similar stocks in the same sector as follows:
RAC Dividend Dates
Please click the table header to sort the data.
No Dividend Dates Found